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Abstract:  
 
Scorpion peptides are well known for their pharmaceutical potential on different targets. These 
include mainly the ion channels which were found to be highly expressed in many diseases, including 
cancer, auto-immune pathologies and Alzheimer. So far, however, the disintegrin activity had only 
been characterized for snake venom molecules. Herein, we present the first short peptide, purified 
from the venom of Buthus occitanus tunetanus, (termed RK) able to inhibit the cell adhesion of 
Glioblastoma, Melanoma and Rat pheochromocytoma to different extracellular matrix (ECM) 
receptors. Anti-integrin antibody assay suggests that RK interacts with both α1β1 and αvβ3 with a more 
pronounced effect for the former. The examination of the primary structure of RK suggests the 
involvement of two motifs: KSS, analogue to KTS which was characterized for α1β1 Snake venom 
disintegrins, and ECD, analogue to RGD which was found to be active on αvβ3. To assess their roles 
in the disintegrin activity of RK, we conducted a computational analysis. The molecular docking 
study shows that RK involves mainly two segments to interact with the α1β1 integrin, but the peptide 
does not implicate the KSS motif in the interaction. The molecular modeling study, suggests the key 
contribution of the ECD segment in the interaction with αvβ3 integrin. 
 
Key words: RK peptide; Adhesion; Molecular modeling. 
1 Introduction 
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Cancer is a bottleneck disease that implicates different physiological processes to exhibit its 
pathological aspect [1]. In the last decades, it was demonstrated that different types of integrins, 
metalloproteinasis and ion channels are highly expressed by many types of tumors. As a result, these 
proteins emerged as interesting biomarkers to detect cancers and as potential pharmacological targets 
to treat them [2]. Particularly, integrins, transmembrane heterodimeric proteins of non covalently 
associated α and β subunits, are implicated in all the processes of carcinogenesis [3]. The association 
between their α and β subunits forms adhesion receptors which binds to the extracellular matrix and 
provide critical adhesive and signalling functions [4]. Integrins are capable to affect cellular functions 
[5] such as cytoskeleton organization, transduction of intracellular signals [6], cell differentiation, 
growth, and apoptosis [7-8]. Different subtypes of integrins have been characterized on the basis of 
their interactions with different motifs of the extracellular matrix implicated in cell adhesion [9]. 
These motifs coordinate the biological responses between endothelial cells, tumor cells and the 
extracellular matrix [10]. In fact, these integrins were first identified on the basis of their ability to 
recognize the RGD amino acid sequence [11-12], and are implicated in cell proliferation, invasion 
and viability. Their ligand binding function is also dependent on the presence of the metal ion (Mg2+, 
Mn2+ and Ca2+) [13].  
Integrins bind to collagen by using their αI Domain, α1β1 and α2β1 represent the most known 
collagen receptors, which are members of integrin family and are structurally very similar [14]. Their 
ligand binds to a Mg2+ ion in the Metal Ion-Dependent Adhesion Site (MIDAS) [15]. α1β1 integrin 
is the principal collagen IV receptor [16] but its contribution in tumor formation and progression is 
poorly defined compared to αvβ3 and α5β1. The critical role of α1β1 integrin in tumorigenicity was 
demonstrated by works elaborated in colon cancer cells that associate with talin and paxillin, resulting 
in the promotion of cancer cell invasion [17]. The ability of multiple polypeptides to inhibit the 
integrin activity was previously discovered for different molecules purified mainly from snake 
venoms called disintegrins. Disintegrins were proven to have anti tumour effects involving 
angiogenesis and cancer metastatic dissemination. The functional classification of disintegrins 
depends on their ability to interact with specific integrins [18], which is determined by the presence 
of a particular integrin-binding motif localized in the hairpin loop, unless they are present in the same 
fold. Functionally, disintegrins can be divided into three classes containing RGD, MLD, and R/KTS 
motifs have been identified [19]. RGD-disintegrins block αvβ3, αvβ1, α5β1 and α8β1 integrins. MLD 
inhibits the physiological functions of α3β1, α6β1, αvβ6, α7β1, α4β1, α4β7 and α9β1 integrins. R/KTS-
disintegrins are a potent and selective inhibitors of α1β1 integrin [20].The extensive screening of many 
scorpion venoms showed a great diversity in their composition with different pharmacological 
potentials. Recently, and for therapeutic purposes, special emphasis was given to bioactive peptides 
which have anticancer activity.  
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 Only a few purified toxins seem to be endowed by the anticancer effects. The Chlorotoxin (CTX) 
isolated from Leiurus quinquestriatus scorpion venom [21], that have been shown to bind specifically 
to glioma cell surfaces as a specific chloride channel blocker and is currently in phase II of human 
trials [22]. Today there are nearly 970 scorpion peptides (available in public databases) described by 
the animal toxin annotation project uniprot [23]. Scorpion peptides are disulfide bond rich molecules 
presenting a sequence length ranging between 23 and about 80 amino acids. The majority of scorpion 
peptides have the sequence signature of the cystine stabilized α/β (CSα/β) motif [24]. Some scorpion 
CSα/β peptides display a remarkable specificity for certain subtypes of ion channels [25]. Scorpion 
venom contains also a significant number of peptides, without the disulfide bridge, that exhibit 
antimicrobial, immunomodulatory, Bradykinin-potentiating and/or hemolytic activities [26]. We have 
recently described the first short 14 amino acid peptide (RK1 peptide), from Buthus occitanus 
tunetanus venom that inhibits tumor cell migration, proliferation and angiogenesis [27]. 
In this work, we isolated a new disintegrin-like homologous peptide from the same venom, targeting 
cancer cell adhesion by acting on integrins. We investigated its anti-tumoral activity and its potential 
interaction with different integrins both in vitro and in silico. 
2 Materials and methods: 
 
2.1 Scorpion venom 
 
Buthus occitanus tunetanus venom was provided in a liquid state by electric simulation of the post-
abdomen of the scorpion, bred in the Beni Khedach area (Tunisia). The pooled venom is kept frozen 
at -20 ◦C in its crude from until use. All reagents were purchased from Sigma- Aldrich® Chemical 
company.  
 
2.2 Purification of RK 
 
Purified RK was obtained from the scorpion venom Buthus occitanus tunetanus by gel filtration G50 
followed by HPLC. Crude venom was dissolved in water and loaded onto a sephadex G50 column 
equilibrated with 0.1M ammonium acetate, pH 8.5. Different fractions were eluted and tested for their 
toxicity on mice. Only a fraction (BotG50) showing a toxic activity [28-29] was then applied onto 
semi preparative reversed-phase HPLC C8 column (10 mm x 250mm, 5 μm, Beckman Fullerton) 
equilibrated in 0.1% trifluoroacetic acid in water, at a flow rate of 1ml/min. HPLC purification of the 
non-retained fraction was performed using an analytical C18 reversed-phase HPLC column (4.6mm 
x 250 mm, 5 microns Beckman). Detection was monitored at 214 nm.  
 
2.3 Mass spectrometry  
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RK was analyzed by MALDI-TOF mass spectrometer (Perspective Biosystems, Inc., Framingham, 
MA). The sample was dissolved in CH3CN/H2O (30/70) with 0.3% trifluoroacetic acid to obtain a 
concentration of 1-10 pmol.μL−1. 
The matrix was prepared as follows: alpha-cyanohydroxycinnamic acid was dissolved in 50% 
CH3CN in 0.3% trifluoroacetic acid/H2O to obtain a saturated solution at 10 μg µL −1. A 0.5 µL 
peptide solution was placed on the sample plate and 0.5 μL of the matrix solution was added. This 
mixture was allowed to dry. Mass spectra were recorded in linear mode, calibrated with suitable 
standards and were analyzed by GRAMS/386 software. 
 
2.4 Amino acid sequence determination and peptide synthesis 
 
Reduction and alkylation of peptides and sequence determination of native and S-alkylated peptide 
were performed as described by Khammessi et al [27-30]. The RK peptide was synthesized by 
Genosphere Biotechnologies (Paris, France). Automated synthesizerd by the Fmoc method on solid 
phase (Merrifield, R. B. 1969. Solid-phase peptide synthesis. Adv. Enzymol. Relat. Areas 
Mol.Biol.32:221.6). Analytical RP-HPLC and MS confirmed the purity (≥ 95%) and molecular mass 
of the synthesized peptide. The peptide stock was diluted in distilled water and kept at -20 °C, and 
quantified by a Nano DropND-1000 V3.5.2 Spectrophotometer at 280 nm. The reduced peptide was 
solubilized in 0.2 M Tris/HCl, pH 8, at 5 mM and stirred under air to allow folding (48 h, 25 °C). The 
target oxidized product was purified to homogeneity by reversed-phase liquid chromatography. The 
chemical identity of synthetic RK peptide was confirmed by mass determination and the elution with 
natural RK peptide after simultaneous injection of both products on analytical reversed-phase HPLC. 
 
2.5 In vivo toxicity test 
 
The in vivo toxicity of RK was tested on 20±2 g C57/BL6 male mice by intracerebro-ventricular 
(I.C.V) route considered to be the most sensitive route to mammals for scorpion toxins [31].  RK was 
diluted in 0.1% (w/v) BSA solutions containing increasing amounts of the peptides in a volume 5µL 
(1, 10, 50, 100 µg/kg). Six mice were used for each dose; two control mice were injected with only 
0.1% BSA in water, to be sure that symptoms are not due to experimental conditions. Effects were 
monitored during 24 hours. All procedures met with the approval of the Institutional Research Board 
of the Pasteur Institute of Tunis. I.C.V administration was performed under ether anesthesia [32]. 
 
2.6 Cell culture 
 
RPMI 1640 medium, Dulbecco's modified Eagle's medium (DMEM), fetal calf serum (FCS), and 
modified Eagle's medium (MEM) were purchased from Lonza (Walkersville, MD). The human 
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fibrinogen, laminin-1 and p-bromophenacyl bromide are from Sigma (Mannheim, Germany). Rat 
type I and IV collagen are obtained from Upstate (Lake Placid, NY) and human fibronectin and 
fibrinogen from Chemicon (Temecula, CA). Human vitronectin was purified according to Yatogho et 
al [32]. Rabbit anti-rat was purchased from Sigma. Cells were first cultured in MEM medium 
supplemented with 10% FBS containing 100 IU/ml penicillin. All cell lines were maintained at 37°C 
in 5% CO2. Rat pheochromocytoma (PC12) cells were cultured in DMEM supplemented with 5% 
FCS and 10% heat inactivated horse serum. Human leukemia (K562) cells were cultured in RPMI 
1640 medium containing 10% FCS. The human cell lines derived from fibrosarcoma (HT1080), 
melanoma (IGR39) and Human colon adenocarcinoma (HT29-D4) were routinely cultured in DMEM 
containing 10% FCS. All cell lines were graciously provided by José Luis (Laboratory of Cell 
Biology, Faculty of Pharmacy, Marseille). 
 
2.7  Cell viability test 
 
Cell viability was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay [33]. MTT solution (500 μg/ml) was added to the culture medium 4 h before the end of 
treatment. Cells were incubated with RK for 72 h, then fixed with 1% glutaraldehyde, stained with a 
solution of 0.1% crystal violet, and lysed with 1% SDS. Absorbance was then measured at 560 nm. 
A control was used in the same conditions, but without RK. 
 
2.8 Cell Adhesion 
 
Cells, in single cell suspension, were added in 96-well plates coated with 10 µg/ml of fibronectin, 
type IV collagen or with 50 µg/ml fibrinogen, for 5 h at 37 °C, as described previously [34-35]. They 
were allowed to adhere to the substrate for 90 min (for U87, PC12, HT1080 and IGR39 cells) or 2 h 
(for HT29-D4 and K562 cells) at 37 °C. Adhesion of K562 cells was performed in the presence of 
1mM MnCl2 and 100 nM phorbol 12-myristate 13-acetate (PMA), in order to activate α5β1 integrin. 
After the achievement of the cell adhesion to the plate wells, we tested the adhesion activity in the 
presence and in the absence of the RK peptide. After washing, adherent cells were fixed, stained with 
0.1% crystal violet and lysed with 1% SDS. Absorbance was then measured at 560 nm. For adhesion 
assays, using blocking antibodies, 96-well plates were coated with 50 µl of rabbit anti-rat IgG (50 
µg/ml), overnight at 4 °C. Wells were washed once with PBS and 50µl of anti-integrin blocking 
antibodies (10 µg/ml) were added for 5 h at 37°C. Then, wells were blocked with a solution of 
PBS/0.5% BSA and adhesion assay was performed as above. 
 
2.9 RK model building  
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The primary structure of the RK peptide was submitted to PEP-FOLD server [36] to establish a de 
novo structure model for the peptide. We also parameterized the building to include the disulfide 
bond formation between C3 and C12 residues. The INPUT sequence was then submitted and the 
returned results were visually explored using PyMOL molecular Viewer [37]. 
 
2.10 Docking ensemble preparation 
 
Two conformational ensembles of the RK peptide (ligand) and the domain I of α1 integrin (DIα1) as 
a receptor were prepared for the cross-docking. The conformational ensemble of the ligand was 
constructed by selecting the structures corresponding to the lowest energies belonging to predefined 
local minimum. All the structures within a difference of 1 kcal/mol of free energy are then selected. 
Clustering analysis applying a hierarchical algorithm was then applied in partitioning the structures 
according to their conformational similarity using a cutoff of 0.15 nm. Each center of these clusters 
is then retained to undergo the docking study. To construct the conformational ensemble for the 
receptor, we selected two structures of the DIα1 domain corresponding receptively to an X-ray 
crystallography structure representing the unbound state [13-38] , and the NMR conformers of the 
bound state for a collagen mimetic peptide (2M32) [39]. For the latter, we removed the coordinates 
of the ligand prior to the docking. The crystal structure was submitted to the EnCoM web server in 
order to improve the exploring of the receptor flexibility [40]. The returned structure were submitted 
to a clustering analysis using a hierarchical algorithm with 0.2 nm cutoff.  
 
2.11 Peptide-protein docking  
 
The peptide-protein docking was effected using ZDOCK 3.0.1 [41]. For each docking, we retained 
the 20000 putative complexes ranked by the default scoring function. All of these underwent a re-
scoring with ZRANK and we selected the best 2000 solutions [42]. Subsequently, we clustered the 
docking poses according to the coordinates of the ligands. Only the clusters with more than 20 
members were retained for further refinement using FoldX [43]. Then the free energy of interaction 
for each putative solution was estimated. The best 20 solutions were retained to proceed to 20 ns 
molecular dynamics simulations using the same protocol used previously for RK peptide. The most 
stable complexes according to the RMSD time evolution (i.e those where the system is equilibrated) 
were then selected. We proceeded then to an additional 8 ns simulation and we re-evaluate the stability 
of the complexes from which the best solution was selected. 
 
2.12 Molecular dynamics  
 
The molecular dynamics simulation was run using Gromacs 5.1. The Gromos 53a6 force field [44] 
was used to assign the molecular mechanics parameters to the RK peptide atoms. The simulation 
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system consists of an octahedron box in which RK peptide occupies its center with a 12 Å cutoff 
between any solute atoms and the edge of the box. The system was solvating with SPC water type 
and was brought to neutrality using an appropriate number of counter-ions. To remove the bad 
contacts resulting from constructing the system, we apply an energy minimization stage in 
conjunction with positional restraints on the heavy atoms of the system. It consists of 1000 steps of 
steepest descent minimization. All the positional restraints were then removed before running a 
second stage of conjugate gradient energy minimization of 200 steps. Particle Mesh Ewald 
approximation was applied and a cutoff of 12 Å was used to reduce the computation concerning the 
non bonded interactions. The hydrogen atoms bonds were modeled under the LINCS containing 
algorithm to allow the use of a 2 fs (femtosecond) time step in running the molecular dynamics.  
The system was then equilibrated under NVT conditions were position restraints were applied for 40 
ps (picosecond). They were then removed and the simulation continued for another 20 ps until the 
desired temperature was reached (300 K). The simulation was then resumed in the NPT ensemble by 
activating the Parrinello-Rahman pressure barostat with a coupling time of 2 ps during 100 ps. This 
was sufficient for the system to reach the desired pressure of 1 bar. The production stage was then 
carried for 300 ns time to generate the trajectory.  
 
2.13 Statistical analysis:  
 
All values are expressed as mean ± standard deviation (SD). All the statistical significance of 
differential findings between experimental and control groups was determined by 2way ANOVA test 
except for the dose/response assay of RK disintegrin activity on the cell lines which was computed 
using a Student's t test. The analysis was made using Graph Pad Prism 5.0 software. P < 0.05 was 
considered statistically significant and is indicated with asterisks over the value (*:p < 0.05; **:p < 
0.01; ***p < 0.001).  
 
 
3 RESULTS 
3.1 Purification of the peptide  
 
RK was substantially purified from the Buthus occitanus tunetanus scorpion venom by a first stage of 
gel filtration on a Sephadex G-50 column chromatography as previously described [29]. The toxic 
fraction (BotG50) obtained from this separation was purified by high performance liquid 
chromatography (HPLC) using a semi preparative C8 column. The fraction eluting at 19-22 min (Fig. 
1A), was further purified (using an analytical C18 reversed-phase HPLC column. The component eluted 
at 33.5 min (Fig. 1B) was homogeneous, as indicated by mass spectrometry analysis and amino acid 
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sequencing. It is designated RK. An analytical HPLC run of RK showed a single symmetric peak (Fig. 
1C). 
 
3.2 Sequence determination of RK and peptide synthesis  
 
(RKs) The automatic Edman degradation of 25 pmol of native RK was performed with a reproducible 
yield of 95% during 17 cycles. 50 pmol of S-alkylated-protein was used to confirm without ambiguity 
the determined sequence, and to identify cystein positions. RK is a short peptide composed of 17 amino 
acid residues containing two cystein residues (Fig. 1D). The experimental molecular mass of native RK 
(1780.03 Da) obtained by MALDI-Tof mass spectrometry (supplementary data 1), is nearly identical to 
the average theoretical molecular mass calculated for the peptide with Oxidize cysteines form (1780.021 
Da). This shows that the two cysteine residues at position 3 and 12 are involved in intramolecular 
disulfide bonds. Due to its very low concentration in venom (0.01% of the proteins), RK was chemically 
synthesized. After renaturation, the synthetic RK (RKs) was eluted with natural RK on analytical C18 
reversed-phase HPLC. Mass spectrometry RKs gave an experimental value of 1780.05 Da, which is in 
agreement with the natural RK molecular mass.  
 
3.3 In vivo toxicity and tumor cells viability 
 
Evaluation of the toxicity of RK and RKs revealed that both peptides do not exhibit any toxicity up to 
100 μg/kg body weight as determined by intracerebro-ventricular injection during 24 hours of 
monitoring the mortality and the side effects. RKs was tested on the viability of glioblastoma (U87), 
melanoma (IGR-39) and Rat pheochromocytoma (PC12) cell lines using the MTT assay. At 100 μM 
concentration, RKs does not affect the viability of all three cell lines including after 24h, 48h or 72h 
incubation time (Fig 2). 
 
3.4 RKs inhibits cell adhesion 
 
In order to investigate the effects of RKs, we performed cell adhesion assays by using a large array of 
purified ECM proteins (collagen IV (Coll IV), fibronectin (Fn), fibronogen (Fg), laminin-1 (Lam)) and 
the non-specific substratum Poly-L-Lysine (PLL). RKs blocked notably the adhesion of human 
glioblastoma cells U87 (Fig. 3A) and melanoma cells IGR39 (Fig. 3B) to fibrinogen and fibronectin, 
while no effect could be observed on collagen IV or laminin. RKs was able to inhibit adhesion of Rat 
pheochromocytoma cells (PC12) only to type IV collagen (Fig. 3C). Moreover, no inhibition could be 
observed on the integrin-independent substratum, poly-L-lysine, suggesting that the effect of RKs may 
involve the integrin family as adhesion receptors. As shown in Fig. 4A, RKs has the highest activity on 
PC12 cell adhesion to collagen IV. Inhibition of adhesion occurs in a dose-dependent manner with an 
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IC50 value of 4.84 µM. RKs blocked notably the adhesion of human glioblastoma cells U87 cells to 
fibrinogen and fibronectin with IC50 values of 15 µM and 15.33 µM respectively (Fig. 4B). However the 
inhibitory effect of RKs on IGR39 cells on fibrinogen and fibronectin does not exceed 40% (Fig. 4C). 
3.5 RKs activity is selective to α1β1 and αvβ3 integrins 
 
To identify the possible targeted integrins, we checked the RKs effect on various cell/ECM protein 
pairs involving in each case a unique integrin:  
α1β1 (PC12/type I collagen), α2β1 (HT1080/ type I collagen), α5β1 (K562/fibronectin), αvβ5 (HT29-
D4/vitronectin), αvβ6 (HT29-D4/fibronectin), α6β4 (HT29-D4/laminin) and αvβ3 (HT29-D4 transfected 
by 3 subunit/fibrinogen). As illustrated in Fig. 5A, RKs was not able to alter cell adhesion through α2β1, 
αvβ6, αvβ5, α5β1 and α6β4 integrins, but significantly reduced the adhesive function of α1β1 and αvβ3 
integrins. We tested the effect of function-blocking antibodies against integrins α1β1, αvβ3 and α5β1 on 
U87 cell adhesion to RKs used as a substrate. As shown in Fig. 5B, only antibodies against α1β1 (60%), 
and αvβ3 (20%) abolished U87 cells attachment. Interestingly, the synthetic RGD peptide (1 mM) was 
able to inhibit more than 80% of human glioblastoma cell adhesion on RKs (Fig. 5B). These results 
suggest that the interaction between RKs and cells might involve an RGD-like motif. 
 
3.6 Computational study 
 
To understand the structural behavior of the RK peptide, we constructed a tridimensionnel structure 
model using PEP-FOLD server which applies a de novo approach. Since, we were not able to detect 
any significant homologous structure in the Protein Data Bank. PEP-FOLD server returned five 
different structures for RK. We selected the one which presents a disulfide bond closure between 
residues C3-C12. The Cα (The alpha carbon) distance between each of these amino acids is about 5.9 
Å (Angstrom) which still in the cutoff range of disulfide bond formation (4.4 to 6.8 Å). The structure 
of the RK peptide consists of 3 sub-segments. The first one corresponds to the dipeptide I1D2. The 
second one is the segment flanked by the two cystein residues (C3GTVMIPSEC12) which harbors a 
one-turn α helix consisting of residues 9-12. The third sub-segment is the C-terminal end 
corresponding to the DPKSS sequence (Fig. 6A). Except for the two cystein residues, all the amino 
acids of RK are solvent exposed. The Accessible surface area calculated for each residue using 
GETAREA shows a minimum of exposure for E11 (53%) and a maximum (100%) for T5, P8, S16 and 
S17. 
3.7 Molecular dynamics of the RK peptide 
 
To gain more insight of the conformational properties of RK, we run a molecular dynamics simulation 
of 300 ns (nanosecond). The RMSD (Root Mean Square Deviation) of the peptide Cα atoms shows 
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broadly three phases on the plot. The first phase is very short, consisting of an equilibration ending 
at the 8th nanosecond of the simulation. The second plateau phase lasts between the 8th and the 52nd 
nanosecond where the RMSD fluctuate approximately around an average value of 3.8 Å relative to 
the starting structure. Until the end of this phase, the peptide preserves the overall conformation of 
the initial structure, mainly the one turn α helix. The following phase lasts for the rest of the trajectory 
where the RMSD values increased significantly to reach an average of 6.8 Å but the values can reach 
more than 7 Å. In fact, The RMSD at this phase is not as stable as its predecessor. We also noticed 
that RK peptide loses the overall initial conformation at this phase, in which the segment between the 
two cysteins shows a disordered structure (Fig. 6B). To characterize the flexibility of RK, we 
calculated the RMSF values per Cα atom. The C-terminal end of the peptide consisting in S16 and S17 
residues is the most flexible segment of RK. These amino acids show an RMSF values of 4.8 and 7.0 
Å, respectively (Fig. 6B). Residues 12-15 are the least flexible with RMSF (Root Mean Square 
Fluctuation) values ranging between 2.7 and 4.8 Å. The RMSF values for the residues of central 
segment, 4-12, seem to be more uniform which could be the result of a collective behavior of these 
amino acids. In addition to the previous analysis, we established the energy landscape of the peptide 
based on the radius of gyration and the RMSD values as reaction coordinates. The Fig. 6C shows that 
the peptide describes mainly two low energy wells. The first one is the largest in which the 
conformation with the lowest energy preserves the one turn α helix. The well is highly populated and 
corresponds to a global minima. The second well is not as much populated as the first well in which 
the conformations present low energy values and corresponds to local minima. The two wells are 
separated by two other metastable local minima. The well representing the global minima of the free 
energy landscape of RK structure served to construct the docking ensemble of the ligand. 
 
3.8 Peptide-protein docking  
 
The clustering of the RK structure models leads to an ensemble of 13 structures. The receptor 
structure used in this study is the domain I of α1 integrin (DIα1). It consists of an inserted segment 
near the N-terminus found only in α1, α2 and α12 integrin sequences. For instance, in contrast to αvβ3 
the MIDAS (metal-ion-dependent adhesion site) is harbored in DIα1 for the α1 integrin by which it 
interacts with the extracellular collagen molecules. There are eleven structures in NMR ensemble of 
DIα1 (PDB code: 2M32). To these, we added three other conformations resulting from the output of 
ENCoM server after submitting the crystal unbound structure of DIα1 (PDB code: 1PT6). As a result, 
a total number of 14 receptor conformers were processed in this study. Consequently, we affected a 
number of 182 (13 for the ligand vs. 14 for the receptor) docking and a total of 364000 complexes 
were evaluated using the ZRANK scoring function. We end up with 14 conformers. At the final stage 
of the docking study we run molecular dynamics simulations for nine complexes of 10 ns. Only three 
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of them show a stable RMSD time evolution. The free energy of interaction, estimated by PRODIGY 
web server [45], are of -7.0, -7.3 and -8.4 kcal/mol. The docking solution with the lowest binding 
energy shows also a very stable profile of RMSD time evolution. In fact, the complex Cα RMSD 
fluctuates around 2.5 Å (Fig. 7A) starting from the second ns to the end of the simulation. We propose 
this docking solution as a model of interaction between the RK peptide and (DIα1). The interaction 
interface between the peptide and the receptor covers the largest part of the binding site of the 
collagen. The I2 and D2 residues interact with the C Loop of DIα1. M7 of RK seems to play an 
important role in the interaction. Its side chain occupies a small cavity situated away from the collagen 
interaction site. The cavity results from the 3D arrangement of two segments: 181-187 and 243-247 
of the integrin (Notice that the amino acids numbering is based on the Uniprot accession P56199). 
W188 residues forms the interior of the cavity interacting with the methyl group of M7. 
 
4 Discussion 
 
In this study, we isolated and characterized RK, from the Buthus occitanus tunetanus scorpion venom 
targeting the cell adhesion activity by acting on integrins. To our knowledge, this is the the first 
disintegrin-like peptide purified from a scorpion venom. Interestingly, RK peptide is unique among 
the variety of known peptides purified from scorpion venoms in terms of its structure. It is a small 
peptide of 17 amino acids (IDCGTVMIPSECDPKSS) containing a single disulfide bond.  
Compared to our previously characterized peptide RK1 (IDCSKVNLTAECSS) [27], RK has a 
sequence identity of 47%. The conserved residues are localized mainly at the C and N terminal ends 
including the disulfide bridge forming cysteins. With such similarity, it is likely that both peptides 
share a homology relationship. However, more evidences would be required to confirm this. RK may 
represent the first member of a new group of scorpion peptides. Interestingly RK did not show any 
toxicity a dose of 100 µg per kg mice body weight. It is also non cytotoxic until 100 µM concentration. 
RK cause the detachment of three cell lines on different ECM proteins. The ineffectiveness of the RK 
on the non specific substratum poly-L-lysine coated plates suggests that the inhibition effect of 
tumoral cells adhesion, by RK peptide, is integrin dependent. High levels of αvβ3, α5β1 and α3β1 are 
expressed in U87 [46], while IGR-39 highly expresses α2β1 and αvβ5 integrins and modestly expresses 
αvβ3 [47]. The disintegrin activity of RK on U87 and IGR-39 would be linked to an effect on αvβ3 
integrin. This could explain why a more important effect is exhibited by the peptide on U87 compared 
to IGR39. The lack of a significant activity on Fibronectin coated plates on IGR39 seems to be 
unlikely at first glance as we expected for the inhibition effect of RK to be similar on both Fibrinogen 
and Fibronectin like we did observe in U87. However these results might be explained by the fact 
that IGR39 expresses high levels of αvβ5 which can bind to Fibronectin though it is more specific to 
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vitronectin [48] and for such reason, the cell can still adhere to the extracellular matrix even in the 
presence of RK. A snake venom anti-adhesion effect of IGR39 was previously reported for lebectin, 
a C-type lectin. In contrast to RK, lebectin is only active on fibronectin and fibrinogen matrix types 
but not on collagen I and IV [49].  
RK peptide disintegrin activity on U87 was evaluated at IC50 values of 15 µM and 15.33 µM 
receptively for Fibrinogen and Fibronectin. The assay on PC12 cell line shows an anti adhesion 
activity on collagen IV coated plates, while no significant effect is noted for the rest of the ECM 
proteins. PC12 expresses α1β1 and α3β1 integrins, both are able to bind laminin in vitro, but only α1β1 
can interact with type I and type IV collagen [50]. Therefore, in addition to αvβ3 we suggest in our 
study that RK acts on α1β1 integrin. As a comparison, the anti-adhesion to fibrinogen and fibronectin 
of PIVL (7691 Da), a snake venom disintegrin targeting αvβ3, on U87-cells was evaluated to similar 
IC50 of about 250 nM and 300 nM respectively [51].  
The similar IC50 values might suggest also that RK inhibits the activity of a common target receptor 
for both Fibrinogen and Fibronectin which we suggest to be the αvβ3 integrin. This is supported by 
the previous calculation of the association rate constants of fibrinogen and fibronectin to αvβ3 integrin 
which are also very similar, evaluated at 2.49 + 0.8 x 104 M-1 s-1 and 2.63 +- 0.05 x 104 M-1 s-1, 
respectively [52]. The antibody assay, confirms that both integrins are potential targets for the 
scorpion peptide. To our knowledge, RK is the first biomolecule demonstrating the dual activity on 
α1β1, which binds to collagen IV, and αvβ3 which binds to all ECM macromolecules presenting the 
RGD motif (vitronectin, fibronectin, fibrinogen, osteopentin, and bone sialoprotein) [53].  
We though, that such property might be caused by the presence of one or two functional motifs 
described for the snake venom disintegrin. RK sequence contains two potential disintegrin motifs: 
ECD and KSS. Indeed, the ECD motif was previously described in Acurhagin-C to be responsible 
for the inhibition of the αvβ3 mediated endothelial cell adhesion to extracellular matrix [54].  
Furthermore, the peptidomimetic of 12 amino acids, issued from the parent ECD loop carrier in 
Acurhagin-C purified from Formosan Agkistrodon acutus venom, showed similar disintegrin activity 
to RGD motif containing peptide [55]. ECD motif was also described in Alternagin-C, and Leberagin-
C [56]. On the other hand, the KSS segment in RK could be is similar to KTS motif which is thought 
to be responsible for the α1β1 disintegrin activities for Obtustatin, Viperistatin and Lebestatin [57]. 
The importance of KTS motif was also corroborated in short linear peptide constructions [58]. To 
investigate the expected interaction of RK with α1β1 and αvβ3 integrins, we conducted computational 
studies. The molecular dynamics simulation of RK highlights the conformational flexibility of the 
peptide which allows it to adopt multiple stable states.  
The free energy landscape shows a dense populated global minimum with a large bottom. Such 
characteristic allows a great adaptability toward the binding site of α1β1 integrin (Fig. 7). The latter 
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has the property to undergo a structural rearrangement upon the binding of collagen IV notably for 
the C loop as concluded by the crystal and NMR solution of the integrin [59-60-61-62]. The binding 
to α1β1 could then be ensured favorably enough even if the peptide structure shifts significantly from 
the global minimum conformation which corresponds to a low drifts in the energy of the system. This 
property also, imply that the RK peptide must preserve a minimum specific set of contacts with high 
structural stability, in order to interact with the integrin.  
The RMSF profile suggests that the central segment of the peptide, limited by the positions of the 
two cystein residues, are stable during the molecular dynamics simulation. Particularly, the segment 
V6, M7 and I8 of the peptide might be critical to ensure the minimal contacts required for the 
interaction with α1β1 regarding also the results from the docking (Fig. 7). The local conformation of 
the segment corresponding to a turn-like structure that remains stable during the 300 ns of molecular 
dynamics simulation. It allows to the M7 side chain to preserve a high level of solvent exposure but 
also to minimize the structural constraints with other atoms of the peptide.  
These properties are essential for the interaction with the small hydrophobic pocket on the surface of 
the integrin. The low flexibility in the 12-15 segment is also essential to stabilize the structure of K15 
residue. Such stability might allow the formation of the salt bridge with E285 amino acid of DIα1. The 
position of the S16 and S17 residues at the C-terminal end of the sequence causes a high instability. In 
addition, based on the protein-peptide docking study, none of the final retained solutions shows any 
critical implication of the KSS segment in the interaction with the integrin. Therefore, we suggest 
that the interaction of RK peptide with α1β1 integrin does not implicate the KSS segment. 
Our results are in accordance with those obtained with the snake venom disintegrin when mutagenesis 
study demonstrates that the substitution of KTS with AAA sequence in obtustatin, do not allow the total 
loose of its activity, compared to the wild type obtustatin [63], although this motif has been earlier 
proposed as the functional amino acid triplet for its activity [64]. These findings, suggest that the 
interaction mechanism of the snake venom disintegrin with α1β1 might not rely only on the KTS triplet 
and that other critical residues might be involved in the formation of the complex. In the absence, of any 
interaction model of α1β1 snake venom disintegrin, the mechanism is still to be investigated. The 
incubation of U87 with RGD peptide coated plates in the presence and the absence of RK suggests that 
both peptides share the same binding site on αvβ3. Consequently, we investigated the involvement of the 
ECD segment of RK in the interaction with the integrin. The rational behind this choice is the similarity 
with the same motif described in other snake disintegrin inhibiting the same receptor [65-55-58]. Our 
results showed that RK was able to sample a set of structures among the molecular dynamics ensemble 
for which the ECD segment has very similar geometric property compared to RGD in the co-crystal 
structure [66-67] (Fig. 8A). In addition, the conformations with the lowest clash score correspond also 
to ideal geometries of interactions with the αvβ3 integrin (Fig. 8B). This in fact suggests that RK is able 
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to engage the ECD segment in the interaction with RGD binding site without been hindered by the other 
residues of the same peptide. Therefore we suggest that, ECD might be the functional segment which 
controls the interaction with αvβ3 integrin (Fig. 8C). However, the conformations with very similar RGD 
geometry for the defined reactions coordinates in our computational analysis are not densely represented 
among the total ensemble sampled in the molecular dynamics simulation. This in fact, can explain the 
low inhibition activity of RK toward αvβ3 compared to α1β1. To compare the structure-function 
relationship of RK peptide to our recently characterized short scorpion peptide RK1, we modeled the 
structure of the latter using the pep-Fold server [36].  
To our surprise RK1 presents the exact same fold of RK which suggest that some functional features are 
shared between the two peptides (supplementary data 2A). Indeed, the sequence alignment revealed 
the presence several conserved segments, including the N-terminal IDC motif, V6, EC segment and the 
C-terminal SS segment. However, RK presents a DPK sequence which is absent in RK1 and several 
other divergent segments which harbors key amino acids in the interaction with the receptors. We 
generated a homology based complex of RK1 with α1β1 and αvβ3 integrins. Indeed, we found it very 
unlikely for the RK1 peptide to interact with alpha1 integrin in the same manner. In fact, RK1 lacks the 
key M7 amino acid substituted by a polar N7 residue which is incapable to establish the steric interactions 
with the exposed pocket of the integrin (supplementary data 2B). The importance of the hydrophobic 
interaction made with this small hydrophobic pocket was recently highlighted  in Lebetin 2 which 
involves a Trp residue to stabilize the complex with alpha1 integrin [68]. Moreover, RK1 peptide lacks 
the K15 amino acids, which establishes a tight interaction with the receptor via a salt bridge formation 
in RK peptide. The homology based complex of RK1 with αvβ3 that the ECS segment would not replace 
the ECD motif in RK. The substitution of Asp by a Ser residue would cause the loss of coordinating the 
Mg++ ion in the MIDAS center (supplementary data 2C). 
This study was the first to describe scorpion peptide with dual disintegrin activity on α1β1 and αvβ3 
integrins. This double effect of RK is due to the presence of contiguous motifs ECD and KSS. It is to 
highlight that selective blockade of α1β1 and αvβ3 integrins is a desirable goal for the therapy of a number 
of pathological conditions including essentially cancer and tumor angiogenesis. 
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LEGENDS TO FIGURES 
Figure 1: Purification of RK from the venom Buthus occitanus tunetanus. 
(A) Purification of BotG50 on semi preparative C8 reverse phase HPLC column. Fractions 19-22 
min was collected. (B) Separation of fraction 19-22 min on C18-RP-HPLC, fraction eluted at 33.5 
min was collected. (C) Final purification step to ensure the purity of peak eluting at 33.5 min (RK). 
(D) Amino acid sequence of RK. 
 
Figure 2. Cell viability.  
PC12 (A), IGR39 (B) and U87 (C) cells incubated for 72 h with different concentrations of RK. 
MTT solution was then added for 4 h. The MTT solution was removed and replaced with 100 μL 
of DMSO into each well in order to dissolve the precipitated formazan crystals 100 μl SDS 1%. 
Finally, the absorbance was measured at 560 nm. All data shown are mean (±SD) from 3 
experiments (n=3) performed in triplicate at different times. 
 
Figure 3. RK inhibits cell adhesion.  
Glioblastoma cells U87 (A), Melanoma cells IGR39 (B) and Rat pheochromocytoma cells PC12 
(C) Were then added to 96-well microtiter plates coated with different ECM proteins (type IV 
collagen, fibrinogen (Fg), fibronectin (Fn), laminin I (LnI)) or poly-L-lysine and allowed to adhere 
for 1 h at 37 °C. After washing, adherent cells were stained with crystal violet, solubilized by SDS 
and absorbance was measured at 560 nm. All data shown are mean (±SD) from3 experiments (n=3) 
performed in triplicate at different times 
 
 
Figure 4. RK inhibits integrin-mediated functions in tumour cells. 
After washing, adherent cells were stained with crystal violet, solubilized by SDS and absorbance 
was measured at 560 nm. Glioblastoma cells U87 (A), Melanoma cells IGR39 (B) and Rat 
pheochromocytoma cells PC12 (C), were preincubated with 5, 10, 15, 20 μM and 30 μM of RK for 
30 min at room temperature and then added to wells coated with 10 mg/ml fibronectin (Fn), 50 
mg/ml fibrinogen (Fg) or 10 mg/ml type IV collagen, (Col IV) and allowed to attach for 1 h at 
37 °C. Data shown are means (±SD) from 3 experiments (n=3) performed in triplicate at different 
times.  
 
Figure 5. The effect of RK on various integrins in cell adhesion assays.  
(A) Adhesion assays were performed with various cells/ECM protein pairs involving unique 
integrins: α1β1 (PC12/type I collagen), α2β1 (HT1080/type I collagen), α6β4 (HT29-D4/laminin), 
αvβ6 (HT29-D4/fibronectin), αvβ3 (HT29 D4/fibrinogen), αvβ5 (HT29-D4/vitronectin) and α5β1 
(K562/fibronectin). Cells were preincubated without or with 15µM of RK for 30 min at room 
temperature. Cells were then added to 96-well microtiter plates coated with 5 mg/ml fibronectin, 
vitronectin or laminin-1, with 10 mg/ml type I collagens or with 50 mg/ml fibrinogen and allowed 
to adhere for 1.30 or 2 h at 37°C. After washing, adherent cells were stained with crystal violet, 
solubilized by SDS and absorbance was measured at 560 nm. (B) Cells incubated without or with 
10 μg/ml antibodies against α1β1, αvβ3, α5β1 or β3, with 1 mM GRGDSP peptide (RGD peptide), 
all experiments were performed in triplicate. Data shown are means (±SD) from 3 experiments 
(n=3) performed in triplicate at different times. 
 
Figure 6. Molecular modeling and molecular dynamics of RK peptide.  
(A) We present the predicted model returned by the PEP-FOLD server. The Cα atoms of each of 
the residues are indicated in spheres. The disulfide bond between the 3rd and the 12th amino acid is 
colored in red. (B) RMSD time evolution (upper panel) and RMSF profile (lower panel) of RK 
peptide calculating for a molecular dynamics trajectory of 300 ns. (C) Potential of mean forces of 
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the RK peptide calculated from the molecular dynamics simulation. The reaction coordinates 
consist of the radius of gyration (Rg) and the RMSD values relative to an average structure 
computed from the 300 ns simulation time.  
 
Figure 7. Peptide-Protein docking of RK with α1β1.  
(A) RMSD time evolution of the best retained complex between RK and α1β1 simulated for 10 ns. 
(B) Interaction of RK peptide (red) with the collagen IV binding site on the α1β1. (C) The key 
interaction with the integrin is expressed in more details. The M7 residue is capable to interact with 
a small hydrophobic pocket on the surface of the integrin formed by the residues in yellow. We also 
demonstrate the interaction of I1 and I2 with the C-loop and the salt bridge between K15 and E285.  
 
Figure 8. Analysis of the interaction of RK with αvβ3. 
(A) We fitted the atoms of the ECD segment from each snapshot the molecular dynamics trajectory 
of RK for those of the RGD coordinates of the 1L5G PDB structure. The ROSETTA clash score 
was then calculated. The reaction coordinates consist of the distance between E11 CA and D13 CG, 
and the angle between E11 CA, C12 CA and D13 CG. (B) The conformation of RK with the least 
RMSD value is presented along with RGD peptide (yellow sticks). (C) The complex of RK with 
αvβ3 was constructed by fitting the conformation corresponding to the lowest clash score of the 
ECD segment with the RGD coordinates of the cilengetide from the PDB structure 1LG5. 
 
Figure supplementary data2. Comparative in silico analysis of RK (IDCGTVMIPSECDPKSS) 
and RK1 (IDCCKVNLTAESS) peptides.  
(A) Structural superposing between the two models of RK (cyan) and RK1 (green) peptides using 
PEP-FOLD2 method. Side chains of RK1 residues are shown. (B) We generated a homology based 
peptide-protein complex between RK1 and α1 integrin. The procedure consists of using the 
structure of RK in complex with the integrin as a template and a model of RK1 was generated 
using MODELLER. We believe that this approach is rational since we demonstrated with 
molecular dynamics that the structure of RK peptide is highly flexible and therefore using the 
structure of RK1 generated by PEP-FOL 2 would not be a better choice. The homology based 
method allows also to normalize the comparison relative to the RK-α1 complex as a reference 
state. We demonstrate in the figure how the N7 residue is not capable to optimize the steric contact 
with the nearby interaction pocket. Also by the absence of K15 residue, RK1 is not capable to 
establish a salt bridge complex with E285 residue of α1 integrin. (C) Using the same method 
described in (B) we generated a complex between RK1 and αvβ3 integrin. RK and RK1 as well as 
their corresponding labels are colored in yellow and cyan respectively. The S13 residue in the ECS 
segment is likely not able to stabilize the interaction with the MIDAS site of the integrin. The 
position of the Calpha atom of S13 is shifted considerably from the equivalent position of D13 of 
RK peptide. 
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Supplementary material 
 
 Figure:  The experimental molecular mass of native RK (1780.03 Da) obtained by 
MALDI-Tof mass spectrometry. The profile corresponds to MALDI-TOF mass spectrometry 
analysis of the RP-HPLC peak containing RK. 
 Figure:    Comparative in silico analysis of RK (IDCGTVMIPSECDPKSS) and RK1 
(IDCSKVNLTAECSS) peptides. 
    
 The retained complex between RK peptide and DIα1 domain: "alpha1bet1-RK.pdb"   
 Description of the interactions between RK and DIα1 domain. This file can be generated 
with PyMOL, version 1.7.2.1 : "interaction_d1l1-RK.pse" 
 Trajectory file for the molecular dynamics simulation of RK. The solvent molecules and 
the counterions were stripped from the file to decrease its size: md_300ns_nowater.xtc 
  The gromacs coordinates file of RK used to read the xtc trajectory with VMD molecular 
viewer: "RK.gro" 
 The structure from which we simulate the molecular dynamics trajectory: "RK_start.pdb" 
 The structure from which we simulate the molecular dynamics trajectory:  "RK_start.pse" 
 A tab separated file, used to generate the figure 8A: "avb3_interaction_study.tsv" 
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Supplementary data 2: 
 
 
 
 
 
Figure supplementary data2. Comparative in silico analysis of RK (IDCGTVMIPSECDPKSS) 
and RK1 (IDCCKVNLTAESS) peptides.  
(A) Structural superposing between the two models of RK (cyan) and RK1 (green) peptides using 
PEP-FOLD2 method. Side chains of RK1 residues are shown. (B) We generated a homology based 
peptide-protein complex between RK1 and α1 integrin. The procedure consists of using the 
structure of RK in complex with the integrin as a template and a model of RK1 was generated 
using MODELLER. We believe that this approach is rational since we demonstrated with 
molecular dynamics that the structure of RK peptide is highly flexible and therefore using the 
structure of RK1 generated by PEP-FOLD2 would not be a better choice. The homology based 
method allows also to normalize the comparison relative to the RK-α1 complex as a reference 
state. We demonstrate in the figure how the N7 residue is not capable to optimize the steric contact 
with the nearby interaction pocket. Also by the absence of K15 residue, RK1 is not capable to 
establish a salt bridge complex with E285 residue of α1 integrin. (C) Using the same method 
described in (B) we generated a complex between RK1 and αvβ3 integrin. RK and RK1 as well as 
their corresponding labels are colored in yellow and cyan respectively. The S13 residue in the ECS 
segment is likely not able to stabilize the interaction with the MIDAS site of the integrin. The 
position of the Calpha atom of S13 is shifted considerably from the equivalent position of D13 of 
RK peptide. 
 
RK              IDCGTVMIPSECDPKSS 
RK1             IDCSKVNLTAECS---S 
                ***..* :.:**.   * 
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Sequence alignment between RK and RK1 peptides 
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